Research in Your Backyard

Developing Cures, Creating Jobs

PHARMACEUTICAL CLINICAL TRIALS IN WASHINGTON

Dots show locations of clinical trials in the state.

PhRMA
RESEARCH • PROGRESS • HOPE

Executive Summary

Clinical Trials in Washington

- Biopharmaceutical research companies are conducting or have conducted more than 3,600 clinical trials of new medicines in collaboration with the state's clinical research centers, university medical schools and hospitals (1999 to present).
- Of the more than 3,600 clinical trials, more than 2,000 target the nation's six most debilitating chronic diseases—**asthma, cancer, diabetes, heart disease, mental illnesses** and **stroke**.

"Since cancer took the life of Gilda Radner, we've witnessed amazing advancements in cancer treatment. Clinical trials are an important part of making those advancements possible. Unfortunately, while nearly 20% of cancer patients are eligible for participation in cancer clinical trials, enrollment among adults consistently ranges between 3-5%. More must be done to unlock the incredible potential of clinical trials for patients with cancer and chronic illnesses."

—Anna Gottlieb,
Gilda's Club Seattle

Economic Benefits of Clinical Trials in Washington

According to the 2012 Annual Report of the Washington Biotechnology & Biomedical Association, the state's life sciences sector—including biopharmaceutical and medical technology companies—has had a profound economic impact:

- Job growth of 12 percent since 2007 through 2011, compared to a 2 percent decline in jobs for all other industries.
- Accounts for 34,000 direct jobs in the state and supports a total of 92,000 Washington jobs.
- Washington life sciences firms produce nearly $11 billion a year in goods and services and provide $7 billion in personal income.
- The life sciences industry is Washington's fifth largest industry sector. More than 400 biopharmaceutical and medical technology companies and research institutions are now in the state.

"The numbers in this report are compelling. There is also a quiet and often untold story behind these numbers. This story recognizes the critical role of local volunteers whose choice to participate in clinical trials makes it possible for research and medical discovery to move forward. Too many clinical trials are delayed because not enough people realize how much of a difference their involvement can make. This report recognizes the thousands of courageous men, women and children in Washington state who step forward and partner with our research teams to embrace the promise of a healthier future in our lifetimes by joining a clinical trial. For this we say, thank you!"

—Susan Adler
NW Association of Biomedical Research

About Clinical Trials

- In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration (FDA) to approve treatments.
- Clinical tests of new drugs are conducted in three phases and account for an average of seven of the 10 to 15 years it takes to bring a new drug from development to patients.
- Clinical trials for a given drug or treatment involve thousands of volunteer patient participants, and the generation of tens of thousands of pages of technical and scientific data.
- Clinical trials are responsible for 45 to 75 percent of the $1.2 billion average cost of developing one new cutting-edge biotechnology medicine.
- For patients, the trials offer another potential therapeutic option. Clinical tests may provide a new avenue of care for some chronic disease sufferers who are still searching for the medicines that are best for them.
- Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.
- All clinical trials must be reviewed and approved by an Institutional Review Board (IRB), an independent committee of physicians, statisticians, local community advocates and others to ensure a trial is ethically conduced and patient rights are protected.
- Clinical trial progress reports must be submitted at least annually to the FDA and IRB.
- All facilities that conduct or support biomedical research involving patients must comply with federal regulations and have an IRB.

Clinical Trials in Washington since 1999—Completed and Active

All Clinical Trials	Six Major Chronic Diseases
3,664	2,019

Source: www.clinicaltrials.gov
Note: Search criteria = Washington, Phase I, II, III; industry only. Search performed 12/26/2012.

Clinical Trials in Washington Communities

Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Bellevue	1	—	—	1	11	1
Bothell	—	—	—	—	13	—
Everett	—	3	1	2	—	2
Kennewick	—	11	—	—	1	—
Kirkland	—	1	—	1	16	—
Olympia	—	—	5	—	—	—
Renton	—	1	9	1	—	1
Seattle	6	185	5	21	16	4
Spokane	6	31	17	9	6	3
Tacoma	3	27	10	10	—	5
Vancouver	2	17	—	—	—	—
Wenatchee	—	13	2	—	—	—
Yakima	—	18	—	—	—	—

Source: www.clinicaltrials.gov
Note: Search criteria = Washington, Phase I, II, II; industry only. Search performed 12/26/2012. See Appendix for detailed information about these clinical trials. The numbers in these disease columns are not the same as the totals in the Appendix because some clinical trials are recruiting in more than one city.

Clinical Trials and Chronic Diseases

- Chronic diseases pose the greatest threats to our nation's health and our ability to treat and prevent medical conditions.
- According to the Centers for Disease Control and Prevention, today, in the United States:
  - Patients with chronic diseases **account for 75 cents of every dollar** spent on health care.
  - Chronic diseases are the **leading cause of death and disability.**
  - Chronic diseases are a **leading driver of rising health care costs** with expenses totaling billions of dollars every year.
- Biopharmaceutical research companies are developing new medicines to help treat those conditions that are taking an unprecedented toll on American lives, and many of these medicines are being tested today in clinical trials throughout Washington.
- Since 1999, biopharmaceutical research companies are sponsoring or have sponsored 2,019 clinical trials of potential new medicines in Washington alone for **asthma, cancer, heart disease, stroke, diabetes** and **mental illnesses**. Of these trials, 377 are either not yet recruiting or are just now seeking Washington patients.
- Many of the state's clinical tests involve collaborations with such respected local institutions as the **University of Washington, Seattle Children's Hospital, Swedish Hospital & Medical Center** and the **Fred Hutchison Cancer Research Center.**
- Many of the medicines being clinically tested here are new-generation biotechnology treatments.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	66	11
Cancer	1,062	235
Diabetes	315	39
Heart Disease	154	33
Mental Illness	385	49
Stroke	37	10
Total	**2,019**	**377**

Source: www.clinicaltrials.gov
Note: Search criteria = Washington, Phase I, II, III; industry only. Search performed 12/26/2012. Some clinical trials appear in more than one disease category.

Clinical Trials in Washington

Clinical tests of new medicines are a vitally important part of the drug development and approval process—they account for 45 to 75 percent of the $1.2 billion average cost of developing a new drug and are conducted to determine the safety and effectiveness of that treatment in patients.

Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.

It's essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines when used by patients. The FDA is a vigilant regulatory agency and its pharmaceutical review officers are effective in detecting flawed information.

Questionable or confusing data can lead to lengthy delays in product approval or outright FDA rejection of a new drug.

Biopharmaceutical research companies are looking for the best physicians and research institutions to meticulously help design and conduct their clinical trials to determine whether a medicine is safe and effective. Side effects must be painstakingly documented and a determination made as to whether they occur too often and are dangerous.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	66	11
Cancer	1,062	235
Diabetes	315	39
Heart Disease	154	33
Mental Illness	385	49
Stroke	37	10
Total	**2,019**	**377**

Source: www.clinicaltrials.gov
Note: Search criteria = Washington, Phase I, II, III; industry only. Search performed 12/26/2012. Some clinical trials appear in more than one disease category.

Clinical tests involve three phases and thousands of volunteer patients and are often conducted at multiple sites around the country. In Washington, biopharmaceutical companies are providing funds to have trials conducted by the state's university medical schools, comprehensive cancer centers and clinical trials research centers. According to *U.S. News and World Report,* the **University of Washington** ranked 10th among last year's top 100 research-oriented medical schools in the United States.

Asthma is a debilitating condition for more than 25 million Americans, including 7.1 million children under the age of 18. The toll is also severe in Washington with more than 400,000 adults and nearly 120,000 children suffering from asthma in the state, according to the Washington State Department of Health.

Currently, 11 clinical trials of new asthma medicines are recruiting patients in Washington. Trials are being conducted at the **Asthma Inc.**, in Seattle and **MultiCare Pulmonary Specialists** in Tacoma.

Cancer, the second leading cause of death in the United States, now afflicts nearly 14 million Americans, according to the National Cancer Institute. In Washington, more than 37,000 new cancer cases will be diagnosed this year and 12,390 victims in the state will die, according to the American Cancer Society.

Currently, 235 clinical trials of new cancer medicines are recruiting patients in Washington. Biopharmaceutical companies are collaborating on the tests with such prominent institutions as the **Fred Hutchinson Cancer Research Center**, the **Swedish Cancer Institute** and the **University of Washington Medical Center** in Seattle, the **MultiCare Health System-Research Institute** in Tacoma, the **Cascade Cancer Center** in Kirkland, **Providence Regional Medical Center** in Everett, **Cancer Care Northwest** in Spokane and the **Yakima Valley Memorial Hospital** in Yakima.

Diabetes affects 25.8 million Americans—more than 8 percent of the U.S. population—including 7 million people who are unaware they have the disease. In Washington, more than 300,000 people have been diagnosed with diabetes, according to the Washington State Department of Health. In 2010, diabetes was the cause of death of 1,497 residents.

Currently, 39 diabetes clinical tests are seeking patients in Washington. The trials are being conducted at **Seattle Children's Hospital** and the **University of Washington Medical Center** in Seattle, the **MultiCare Research Institute** in Tacoma, **Mylar Research** in Lakewood, and the **Rainier Clinical Research Center** in Renton.

Heart disease and stroke are the first and fourth leading disease causes of death in the United States and the second and sixth in Washington. According to the American Heart Association, more than 82 million Americans are affected by these diseases. In Washington, in 2011, more than 10,000 residents died from some form of heart disease and 2,554 died from a stroke, according to the Washington State Department of Health.

Currently, 33 heart disease and 10 stroke clinical tests are seeking patients in Washington. The trials are being conducted at **Providence Sacred Heart Medical Center** in Spokane, the **MultiCare Health System Research Institute-Cardiac Study Center** in Tacoma, and the **Swedish Hospital & Medical Center** and the **Seattle-King County Center for Resuscitation Research** in Seattle.

Mental illness affects nearly 60 million Americans suffering from some form of the disease—from anxiety to depression to schizophrenia to eating disorders. In Washington, about 219,000 adults live with serious mental illness and about 71,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness.

Currently, 49 clinical trials are recruiting patients in Washington. The trials are taking place at the **Frontier Institute** in Spokane, the **Summit Research Network** in Seattle, the **Northwest Clinical Research Center** in Bellevue and the **Eastside Therapeutic Resource** in Kirkland.

*Physicians and patients can find out about clinical trials being conducted all over the state in collaboration with local institutions by accessing **www.clinicaltrials.gov**, a data base sponsored by the National Institutes of Health. Information on medicines in development is also available on **www.phrma.org**, the website of the Pharmaceutical Research and Manufacturers of America (PhRMA), under "Clinical Research and Trials."*

New Generation Medicines in Development

Many of the medicines being tested in Washington are cutting-edge biotechnology drugs.

America's biopharmaceutical research companies are using biotechnology to develop hundreds of medicines and vaccines today. And Washington is one of the states where new-generation research and development work is being done.

Through biotechnology, new ways are being developed to not only more effectively treat disease, but also to predict it and eventually preempt it.

Biotechnology medicines are developed through biological processes using living cells or organisms, rather than traditional chemical synthesis, the mainstay of pharmaceutical development for decades.

Such novel treatments use a variety of new approaches to treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology is being used in biotechnology research to provide drug-delivery systems, new treatments and diagnostics.

Many of the medicines in clinical testing at Washington medical schools and research centers feature these technologies. For example:

- A monoclonal antibody for the treatment of cancer
- An antisense medicine for the treatment of cancer.
- A recombinant fusion protein to treat diabetic macular edema.
- A monoclonal antibody in the pipeline targets lupus and various types of cancer.
- A therapeutic vaccine, designed to jump-start the immune system to fight disease, is in development for lung cancer and melanoma.

These are only a portion of the examples of new ways the nation's biopharmaceutical companies and Washington research institutions are working together to attack disease. The biotechnology medicines and vaccines in development promise to push the frontiers of science and potentially bring more and better treatments to patients.

Conclusion

Biopharmaceutical companies' close collaboration with clinicians and research institutions in Washington benefits patients, the state's economy and the advancement of science and patient care. Clinical trials provide stimulating biopharmaceutical research work and a reliable source of revenue for the state's medical schools and research organizations and the medicines being tested are often cutting-edge cell and protein treatments with the potential to be safer and more effective than older chemical compound drugs.

What's more, Washingtonians contemplating participation in clinical trials have a wide range of choices—more than 370 tests of new medicines for the six most debilitating chronic diseases in America are underway in communities large and small all over the state and they are recruiting patient volunteers.

The Drug Discovery, Development and Approval Process

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Clinical Trials

	Discovery/ Preclinical Testing	File IND at FDA	Phase I	Phase II	Phase III	File NDA/BLA at FDA	FDA	Phase IV
Years	**6.5**		**1.5**	**2**	**3.5**		**1.5**	
Test Population	Laboratory and animal studies		20 to 80 healthy volunteers	100 to 300 patient volunteers	1,000 to 3,000 patient volunteers		Review process/ approval	Additional post-marketing testing required by FDA
Purpose	Assess safety, biological activity and formulations		Determine safety and dosage	Evaluate effective-ness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use			
Success Rate	5,000 compounds evaluated			5 enter trials			1 approved	

The Drug Development and Approval Process

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company $1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are usually developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I—Researchers test the drug in a small group of people, usually between 20 and 80 healthy adult volunteers, to evaluate its initial safety and tolerability profile, determine a safe dosage range, and identify potential side effects.

Clinical Trials, Phase II—The drug is given to volunteer patients, usually between 100 and 300, to see if it is effective, identify an optimal dose, and further evaluate its short-term safety.

Clinical Trials, Phase III—The drug is given to a larger, more diverse patient population, often involving between 1,000 and 3,000 patients (but sometime many more thousands), to generate statistically significant evidence to confirm its safety and effectiveness. They are the longest studies, and usually take place in multiple sites around the world.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated $49.5 billion in research and development in 2011.

The Good News– Many Clinical Trials are Still Recruiting

There are 377 clinical trials recruiting in Washington. These trials target the top six chronic diseases and other debilitating diseases affecting Americans and Washingtonians.

Clinical Trials in Washington Communities

Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Bellevue	1	—	—	1	11	1
Bothell	—	—	—	—	13	—
Everett	—	3	1	2	—	2
Kennewick	—	11	—	—	1	—
Kirkland	—	1	—	1	16	—
Olympia	—	—	5	—	—	—
Renton	—	1	9	1	—	1
Seattle	6	185	5	21	16	4
Spokane	6	31	17	9	6	3
Tacoma	3	27	10	10	—	5
Vancouver	2	17	—	—	—	—
Wenatchee	—	13	2	—	—	—
Yakima	—	18	—	—	—	—

Source: www.clinicaltrials.gov
Note: Search criteria = Washington, Phase I, II, II; industry only. Search performed 12/26/2012. See Appendix for detailed information about these clinical trials. The numbers in these disease columns are not the same as the totals in the Appendix because some clinical trials are recruiting in more than one city.

The Good News–Many Clinical Trials are Still Recruiting

(continued)

Asthma—Leading Institutions Conducting Clinical Trials

Asthma, Inc., Clinical Research Center, Seattle

MultiCare Pulmonary Specialists, Tacoma

Cancer—Leading Institutions Conducting Clinical Trials

Benaroya Research Institute, Seattle

Brabant Research, Monroe

Cancer Care Northwest, Spokane

Cancer Research and Biostatistics Clinical Trials Consortium, Seattle

Cascade Cancer Center, Kirkland

Columbia Basin Hematology and Oncology, Kennewick

Comprehensive Clinical Development NW, Tacoma

Evergreen Hematology Oncology, Spokane

Fred Hutchinson Cancer Research Center, Seattle

Group Health Medical Centers, Seattle

Harrison Health Partners Bremerton Hematology & Oncology, Bremerton

Madigan Army Medical Center, Tacoma

Medical Oncology Associates, Spokane

MultiCare Health System-Research Institute, Tacoma

Northwest Cancer Specialists, Vancouver

Northwest Medical Specialties, Tacoma

Peninsula Cancer Center, Poulsbo

Providence Regional Medical Center, Everett

Providence St. Mary Regional Cancer Center, Walla Walla

Puget Sound Cancer Centers, Edmonds, Seattle

Rockwood Clinic, Spokane

Seattle Cancer Care Alliance, Seattle

Seattle Children's Hospital, Seattle

Seattle Urology Research Center, Burien

Swedish Medical Center Cancer Institute, Seattle

Swedish Medical Center Neuroscience Institute, Seattle

Swedish Medical Center Tumor Institute, Seattle

University of Washington Medical Center, Seattle

VA Puget Sound Health Care, Seattle

Virginia Mason Hospital & Medical Center, Seattle

Wenatchee Valley Medical Center, Wenatchee

Yakima Valley Memorial Hospital/North Star Lodge, Yakima

Diabetes—Leading Institutions/Physician Conducting Clinical Trials

Capital Clinical Research Center, Olympia

Larry D. Stonesifer, MD, Federal Way

MultiCare Research Institute, Tacoma

Mylar Research, Lakewood

Northside Internal Medicine Associates, Spokane

Rainier Clinical Research Center, Renton

Rockwood Clinic, Tacoma

Seattle Children's Hospital, Seattle

Sound Medical Research, Port Orchard

Spokane Eye Clinic, Spokane

University of Washington Medical Center, Seattle

Heart Disease—Leading Institutions Conducting Clinical Trials

Heart Institute at Virginia Mason Hospital, Seattle

Kootenai Heart Clinics, Spokane

MultiCare Health System Research Institute/Cardiac Study Center, Tacoma

Providence Sacred Heart Medical Center, Spokane

Seattle Children's Hospital, Seattle

Seattle-King County Center for Resuscitation Research, Seattle

Spokane Cardiology, Spokane

Swedish Hospital & Medical Center/Cardiovascular Research, Seattle

University of Washington Medical Center, Seattle

Mental Illness—Leading Institutions/Physicians Conducting Clinical Trials

Arifulla Kahn, Bellevue

Booth Gardner Parkinson's Care Center, Kirkland

Claire Waltman, MD, Seattle

Eastside Therapeutic Resource, Kirkland

Frontier Institute, Spokane

Northwest Clinical Research Center, Bellevue

Scientella, LLC, Richland

Sleep Medicine Associates, Seattle

Summit Research Network, Seattle

Women's Clinical Research Center, Seattle

Stroke—Leading Institutions Conducting Clinical Trials

Deaconess Medical Center, Spokane

Swedish Medical Center, Seattle

Appendix

The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto *www.clinicaltrials.gov*, the clinical tests database of the National Institutes of Health.

Asthma
(11 clinical trials recruiting)

Study 1:

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

http://ClinicalTrials.gov/show/NCT01576718

Study 2:

Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma

http://ClinicalTrials.gov/show/NCT01747629

Study 3:

A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

http://ClinicalTrials.gov/show/NCT01591044

Study 4:

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

http://ClinicalTrials.gov/show/NCT01508936

Study 5:

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

http://ClinicalTrials.gov/show/NCT01479621

Study 6:

Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

http://ClinicalTrials.gov/show/NCT01737905

Study 7:

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

http://ClinicalTrials.gov/show/NCT01545440

Study 8:

A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

http://ClinicalTrials.gov/show/NCT01545453

Study 9:

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

http://ClinicalTrials.gov/show/NCT01582503

Study 10:

A Study of ARRY-502 in Patients With Persistent Asthma

http://ClinicalTrials.gov/show/NCT01561690

Study 11:

Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

http://ClinicalTrials.gov/show/NCT01008410

Cancer
(235 clinical trials recruiting)

Study 1:

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

http://ClinicalTrials.gov/show/NCT01421472

Study 2:

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

http://ClinicalTrials.gov/show/NCT00858364

Study 3:

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

http://ClinicalTrials.gov/show/NCT01493505

Study 4:

Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT01113970

Study 5:

A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

http://ClinicalTrials.gov/show/NCT01168973

Study 6:

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

http://ClinicalTrials.gov/show/NCT01077154

Study 7:

Study of PX-866 and Docetaxel in Solid Tumors

http://ClinicalTrials.gov/show/NCT01204099

Study 8:

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

http://ClinicalTrials.gov/show/NCT01478594

Study 9:

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

http://ClinicalTrials.gov/show/NCT01492101

Study 10:

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

http://ClinicalTrials.gov/show/NCT00968968

Study 11:

A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

http://ClinicalTrials.gov/show/NCT01288911

Study 12:

Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

http://ClinicalTrials.gov/show/NCT00320710

Study 13:

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

http://ClinicalTrials.gov/show/NCT00696072

Study 14:

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01373164

Study 15:

A Study in Second Line Metastatic Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01183780

Study 16:

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

http://ClinicalTrials.gov/show/NCT01170650

Study 17:

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

http://ClinicalTrials.gov/show/NCT01338012

Study 18:

Efficacy and Safety Study of NeuVax™ Vaccine to Prevent Breast Cancer Recurrence

http://ClinicalTrials.gov/show/NCT01479244

Study 19:

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

http://ClinicalTrials.gov/show/NCT01454089

Study 20:

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

http://ClinicalTrials.gov/show/NCT01610284

Study 21:

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

http://ClinicalTrials.gov/show/NCT01381874

Study 22:

Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/ Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01493843

Study 23:

EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer

http://ClinicalTrials.gov/show/NCT01485848

Study 24:

Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

http://ClinicalTrials.gov/show/NCT01642004

Study 25:

A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After Chemotherapy

http://ClinicalTrials.gov/show/NCT01328951

Study 26:

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

http://ClinicalTrials.gov/show/NCT01565083

Study 27:

ARCHER 1009: A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01360554

Study 28:

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

http://ClinicalTrials.gov/show/NCT01204749

Study 29:

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01522443

Study 30:

Natural Supplements and a Special Diet in Eliminating Growth Hormones Made Outside the Body in Patients With Early-Stage Prostate Cancer, Breast Cancer, or Uterine Cancer

http://ClinicalTrials.gov/show/NCT00910884

Study 31:

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

http://ClinicalTrials.gov/show/NCT01605227

Study 32:

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

http://ClinicalTrials.gov/show/NCT01379534

Study 33:

Safety Study of PLX108-01 in Patients With Solid Tumors

http://ClinicalTrials.gov/show/NCT01004861

Study 34:

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01453153

Study 35:

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

http://ClinicalTrials.gov/show/NCT01220128

Study 36:

Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

http://ClinicalTrials.gov/show/NCT01547299

Study 37:

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

http://ClinicalTrials.gov/show/NCT01510561

Study 38:

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

http://ClinicalTrials.gov/show/NCT01664923

Study 39:

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

http://ClinicalTrials.gov/show/NCT01217697

Study 40:

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01345019

Study 41:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

http://ClinicalTrials.gov/show/NCT00045968

Study 42:

A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01647789

Study 43:

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

http://ClinicalTrials.gov/show/NCT01590719

Study 44:

Study Of Dacomitinib In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

http://ClinicalTrials.gov/show/NCT01465802

Study 45:

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

http://ClinicalTrials.gov/show/NCT00958841

Study 46:

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

http://ClinicalTrials.gov/show/NCT01358877

Study 47:

A Multi-arm Phase I Safety Study of BMS-936558 in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib or Monotherapy Alone in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)

http://ClinicalTrials.gov/show/NCT01454102

Study 48:

A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer

http://ClinicalTrials.gov/show/NCT01322490

Study 49:

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01360840

Study 50:

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

http://ClinicalTrials.gov/show/NCT01451853

Study 51:

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

http://ClinicalTrials.gov/show/NCT01461538

Study 52:

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

http://ClinicalTrials.gov/show/NCT01166490

Study 53:

Immunotherapy Study for Surgically Resected Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01072981

Study 54:

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

http://ClinicalTrials.gov/show/NCT01415960

Study 55:

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

http://ClinicalTrials.gov/show/NCT01361607

Study 56:

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

http://ClinicalTrials.gov/show/NCT01528345

Study 57:

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

http://ClinicalTrials.gov/show/NCT01667536

Study 58:

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+ Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT01698918

Study 59:

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

http://ClinicalTrials.gov/show/NCT01427933

Study 60:

Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

http://ClinicalTrials.gov/show/NCT01234402

Study 61:

Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC

http://ClinicalTrials.gov/show/NCT01673867

Study 62:

Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy

http://ClinicalTrials.gov/show/NCT01521143

Study 63:

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01505530

Study 64:

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01283373

Study 65:

A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

http://ClinicalTrials.gov/show/NCT01351415

Study 66:

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01519804

Study 67:

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT01740336

Study 68:

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

http://ClinicalTrials.gov/show/NCT01555710

Study 69:

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT01663727

Study 70:

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

http://ClinicalTrials.gov/show/NCT01304524

Study 71:

Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

http://ClinicalTrials.gov/show/NCT01285609

Study 72:

A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004 AM4)

http://ClinicalTrials.gov/show/NCT01357161

Study 73:

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

http://ClinicalTrials.gov/show/NCT01387555

Study 74:

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM2)

http://ClinicalTrials.gov/show/NCT01254630

Study 75:

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01483027

Study 76:

SpaceOAR System Pivotal Study

http://ClinicalTrials.gov/show/NCT01538628

Study 77:

A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen

http://ClinicalTrials.gov/show/NCT01497470

Study 78:

NOLAN: Naproxen or Loratadine and Neulasta

http://ClinicalTrials.gov/show/NCT01712009

Study 79:

A Study of Ramucirumab and Paclitaxel in Patients With Solid Tumors

http://ClinicalTrials.gov/show/NCT01515306

Study 80:

A Study in Head and Neck Cancer

http://ClinicalTrials.gov/show/NCT01081041

Study 81:

Pharmacodynamic Study of Abiraterone in the Treatment of Advanced Prostate Cancer

http://ClinicalTrials.gov/show/NCT01508234

Study 82:

Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01577654

Study 83:

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01496742

Study 84:

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

http://ClinicalTrials.gov/show/NCT01747876

Study 85:

A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

http://ClinicalTrials.gov/show/NCT01160744

Study 86:

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

http://ClinicalTrials.gov/show/NCT01273493

Study 87:

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01454934

Study 88:

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

http://ClinicalTrials.gov/show/NCT01231594

Study 89:

A Study Of PF-04449913 In Select Hematologic Malignancies

http://ClinicalTrials.gov/show/NCT00953758

Study 90:

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

http://ClinicalTrials.gov/show/NCT01594723

Study 91:

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

http://ClinicalTrials.gov/show/NCT01345669

Study 92:

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

http://ClinicalTrials.gov/show/NCT01650376

Study 93:

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

http://ClinicalTrials.gov/show/NCT01479465

Study 94:

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

http://ClinicalTrials.gov/show/NCT01472198

Study 95:

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

http://ClinicalTrials.gov/show/NCT00932451

Study 96:

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01360853

Study 97:

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors

http://ClinicalTrials.gov/show/NCT01577745

Study 98:

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01294826

Study 99:

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT01160211

Study 100:

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

http://ClinicalTrials.gov/show/NCT01413113

Study 101:

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

http://ClinicalTrials.gov/show/NCT01629758

Study 102:

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

http://ClinicalTrials.gov/show/NCT01529684

Study 103:

A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

http://ClinicalTrials.gov/show/NCT01507168

Study 104:

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01298570

Study 105:

Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer

http://ClinicalTrials.gov/show/NCT01700400

Study 106:

Vaccine Therapy in Treating Patients With Breast Cancer

http://ClinicalTrials.gov/show/NCT00524277

Study 107:

A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

http://ClinicalTrials.gov/show/NCT01358903

Study 108:

A Study of LY2940680 in Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01722292

Study 109:

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

http://ClinicalTrials.gov/show/NCT01406119

Study 110:

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

http://ClinicalTrials.gov/show/NCT01403064

Study 111:

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

http://ClinicalTrials.gov/show/NCT01063816

Study 112:

A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

http://ClinicalTrials.gov/show/NCT01283516

Study 113:

Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy

http://ClinicalTrials.gov/show/NCT00223665

Study 114:

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

http://ClinicalTrials.gov/show/NCT00920140

Study 115:

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

http://ClinicalTrials.gov/show/NCT01379209

Study 116:

Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC

http://ClinicalTrials.gov/show/NCT00488982

Study 117:

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

http://ClinicalTrials.gov/show/NCT01450761

Study 118:

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

http://ClinicalTrials.gov/show/NCT01235962

Study 119:

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

http://ClinicalTrials.gov/show/NCT01190176

Study 120:

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

http://ClinicalTrials.gov/show/NCT01192165

Study 121:

GSK1120212 Rollover Study

http://ClinicalTrials.gov/show/NCT01376310

Study 122:

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

http://ClinicalTrials.gov/show/NCT01412229

Study 123:

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

http://ClinicalTrials.gov/show/NCT00835978

Study 124:

Multiple Ascending Dose (MDX1105-01)

http://ClinicalTrials.gov/show/NCT00729664

Study 125:

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

http://ClinicalTrials.gov/show/NCT01399840

Study 126:

Phase 1 and 2 Study of PX-866 and Cetuximab

http://ClinicalTrials.gov/show/NCT01252628

Study 127:

Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer

http://ClinicalTrials.gov/show/NCT01440816

Study 128:

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

http://ClinicalTrials.gov/show/NCT01593228

Study 129:

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

http://ClinicalTrials.gov/show/NCT01321346

Study 130:

A Phase 1 Study of LY2787106 in Cancer and Anemia

http://ClinicalTrials.gov/show/NCT01340976

Study 131:

Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

http://ClinicalTrials.gov/show/NCT01470794

Study 132:

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

http://ClinicalTrials.gov/show/NCT01120457

Study 133:

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

http://ClinicalTrials.gov/show/NCT01304784

Study 134:

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

http://ClinicalTrials.gov/show/NCT01468688

Study 135:

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

http://ClinicalTrials.gov/show/NCT01332266

Study 136:

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

http://ClinicalTrials.gov/show/NCT01090414

Study 137:

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

http://ClinicalTrials.gov/show/NCT01307267

Study 138:

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

http://ClinicalTrials.gov/show/NCT01556490

Study 139:

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

http://ClinicalTrials.gov/show/NCT01147809

Study 140:

Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

http://ClinicalTrials.gov/show/NCT00919503

Study 141:

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

http://ClinicalTrials.gov/show/NCT01523587

Study 142:

Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

http://ClinicalTrials.gov/show/NCT01282463

Study 143:

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

http://ClinicalTrials.gov/show/NCT01125800

Study 144:

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

http://ClinicalTrials.gov/show/NCT01378975

Study 145:

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01335399

Study 146:

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

http://ClinicalTrials.gov/show/NCT01002248

Study 147:

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

http://ClinicalTrials.gov/show/NCT01353222

Study 148:

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01441414

Study 149:

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT00821249

Study 150:

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01478048

Study 151:

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

http://ClinicalTrials.gov/show/NCT01393964

Study 152:

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

http://ClinicalTrials.gov/show/NCT00916409

Study 153:

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01199718

Study 154:

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01564537

Study 155:

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/ Dexamethasone in Relapsed/Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01359657

Study 156:

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01583283

Study 157:

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

http://ClinicalTrials.gov/show/NCT01480479

Study 158:

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

http://ClinicalTrials.gov/show/NCT01471782

Study 159:

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

http://ClinicalTrials.gov/show/NCT01498328

Study 160:

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01464034

Study 161:

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT01328626

Study 162:

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01034631

Study 163:

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

http://ClinicalTrials.gov/show/NCT01208662

Study 164:

A Safety Study of Carfilzomib With Cyclophosphamide and Dexamethasone Prior to Autologous Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01660750

Study 165:

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

http://ClinicalTrials.gov/show/NCT01014208

Study 166:

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

http://ClinicalTrials.gov/show/NCT01369329

Study 167:

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

http://ClinicalTrials.gov/show/NCT01592045

Study 168:

Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC

http://ClinicalTrials.gov/show/NCT01668784

Study 169:

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

http://ClinicalTrials.gov/show/NCT01667419

Study 170:

A Phase III Study of Oral LDE225 Versus (vs) Temozolomide (TMZ) in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

http://ClinicalTrials.gov/show/NCT01708174

Study 171:

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

http://ClinicalTrials.gov/show/NCT01672775

Study 172:

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01677390

Study 173:

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma

http://ClinicalTrials.gov/show/NCT01632228

Study 174:

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

http://ClinicalTrials.gov/show/NCT01752933

Study 175:

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

http://ClinicalTrials.gov/show/NCT01140347

Study 176:

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

http://ClinicalTrials.gov/show/NCT00908752

Study 177:

ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

http://ClinicalTrials.gov/show/NCT01287585

Study 178:

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

http://ClinicalTrials.gov/show/NCT01489059

Study 179:

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

http://ClinicalTrials.gov/show/NCT01621490

Study 180:

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

http://ClinicalTrials.gov/show/NCT01343277

Study 181:

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

http://ClinicalTrials.gov/show/NCT01339260

Study 182:

A Study of IMC-3G3 in Soft Tissue Sarcoma

http://ClinicalTrials.gov/show/NCT01185964

Study 183:

A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

http://ClinicalTrials.gov/show/NCT00210665

Study 184:

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

http://ClinicalTrials.gov/show/NCT01327885

Study 185:

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

http://ClinicalTrials.gov/show/NCT01141491

Study 186:

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

http://ClinicalTrials.gov/show/NCT01055496

Study 187:

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

http://ClinicalTrials.gov/show/NCT01295710

Study 188:

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

http://ClinicalTrials.gov/show/NCT01232556

Study 189:

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

http://ClinicalTrials.gov/show/NCT01734512

Study 190:

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

http://ClinicalTrials.gov/show/NCT00752206

Study 191:

A Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT01659021

Study 192:

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

http://ClinicalTrials.gov/show/NCT01321541

Study 193:

A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

http://ClinicalTrials.gov/show/NCT01414855

Study 194:

A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma

http://ClinicalTrials.gov/show/NCT01691898

Study 195:

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

http://ClinicalTrials.gov/show/NCT00910910

Study 196:

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

http://ClinicalTrials.gov/show/NCT00931918

Study 197:

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

http://ClinicalTrials.gov/show/NCT00774345

Study 198:

A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT01421667

Study 199:

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

http://ClinicalTrials.gov/show/NCT01294579

Study 200:

Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

http://ClinicalTrials.gov/show/NCT01200589

Study 201:

A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

http://ClinicalTrials.gov/show/NCT01569295

Study 202:

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

http://ClinicalTrials.gov/show/NCT01349049

Study 203:

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT01188681

Study 204:

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT01578707

Study 205:

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

http://ClinicalTrials.gov/show/NCT01059630

Study 206:

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

http://ClinicalTrials.gov/show/NCT01632852

Study 207:

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

http://ClinicalTrials.gov/show/NCT01468467

Study 208:

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT01363297

Study 209:

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

http://ClinicalTrials.gov/show/NCT01241500

Study 210:

Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT01393106

Study 211:

A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)

http://ClinicalTrials.gov/show/NCT01716806

Study 212:

A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

http://ClinicalTrials.gov/show/NCT01539512

Study 213:

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

http://ClinicalTrials.gov/show/NCT00777036

Study 214:

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

http://ClinicalTrials.gov/show/NCT01177540

Study 215:

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL

http://ClinicalTrials.gov/show/NCT01439347

Study 216:

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT01088048

Study 217:

A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

http://ClinicalTrials.gov/show/NCT01290549

Study 218:

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

http://ClinicalTrials.gov/show/NCT01460160

Study 219:

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

http://ClinicalTrials.gov/show/NCT01398462

Study 220:

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

http://ClinicalTrials.gov/show/NCT01482962

Study 221:

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

http://ClinicalTrials.gov/show/NCT01466179

Study 222:

A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

http://ClinicalTrials.gov/show/NCT00866281

Study 223:

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

http://ClinicalTrials.gov/show/NCT01476787

Study 224:

A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

http://ClinicalTrials.gov/show/NCT01539291

Study 225:

A Moderate to Severe Rheumatoid Arthritis Study

http://ClinicalTrials.gov/show/NCT01721044

Study 226:

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

http://ClinicalTrials.gov/show/NCT00981799

Study 227:

Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen

http://ClinicalTrials.gov/show/NCT01457885

Study 228:

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

http://ClinicalTrials.gov/show/NCT01155817

Study 229:

A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

http://ClinicalTrials.gov/show/NCT01411267

Study 230:

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

http://ClinicalTrials.gov/show/NCT01523977

Study 231:

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

http://ClinicalTrials.gov/show/NCT01614197

Study 232:

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

http://ClinicalTrials.gov/show/NCT00940602

Study 233:

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus Asadjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

http://ClinicalTrials.gov/show/NCT01713946

Study 234:

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease

http://ClinicalTrials.gov/show/NCT01582061

Study 235:

Intravenous Acetaminophen for Craniotomy Patients

http://ClinicalTrials.gov/show/NCT01474304

Diabetes

(39 clinical trials recruiting)

Study 1:

A Study in Patients With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01435616

Study 2:

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

http://ClinicalTrials.gov/show/NCT01680341

Study 3:

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

http://ClinicalTrials.gov/show/NCT01195662

Study 4:

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

http://ClinicalTrials.gov/show/NCT01137474

Study 5:

A Study in Patients With Type I Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01454284

Study 6:

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

http://ClinicalTrials.gov/show/NCT01131676

Study 7:

A Study in Participants With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01468987

Study 8:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

http://ClinicalTrials.gov/show/NCT00968708

Study 9:

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

http://ClinicalTrials.gov/show/NCT01103284

Study 10:

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

http://ClinicalTrials.gov/show/NCT01620489

Study 11:

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

http://ClinicalTrials.gov/show/NCT01691755

Study 12:

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

http://ClinicalTrials.gov/show/NCT01649297

Study 13:

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01683266

Study 14:

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01617434

Study 15:

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

http://ClinicalTrials.gov/show/NCT01664247

Study 16:

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

http://ClinicalTrials.gov/show/NCT01676116

Study 17:

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

http://ClinicalTrials.gov/show/NCT01570751

Study 18:

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01576328

Study 19:

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01204775

Study 20:

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

http://ClinicalTrials.gov/show/NCT01394952

Study 21:

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01719003

Study 22:

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01144338

Study 23:

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

http://ClinicalTrials.gov/show/NCT01621178

Study 24:

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

http://ClinicalTrials.gov/show/NCT01676220

Study 25:

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019 AM2)

http://ClinicalTrials.gov/show/NCT01698775

Study 26:

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

http://ClinicalTrials.gov/show/NCT01704261

Study 27:

A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

http://ClinicalTrials.gov/show/NCT01686620

Study 28:

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

http://ClinicalTrials.gov/show/NCT01487109

Study 29:

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

http://ClinicalTrials.gov/show/NCT01691846

Study 30:

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of Glymera Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

http://ClinicalTrials.gov/show/NCT01658501

Study 31:

Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature

http://ClinicalTrials.gov/show/NCT01497938

Study 32:

The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children

http://ClinicalTrials.gov/show/NCT00875290

Study 33:

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

http://ClinicalTrials.gov/show/NCT01200394

Study 34:

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

http://ClinicalTrials.gov/show/NCT01715818

Study 35:

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

http://ClinicalTrials.gov/show/NCT01496365

Study 36:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

http://ClinicalTrials.gov/show/NCT01147250

Study 37:

A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

http://ClinicalTrials.gov/show/NCT01683409

Study 38:

Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021 AM1)

http://ClinicalTrials.gov/show/NCT01564459

Study 39:

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

http://ClinicalTrials.gov/show/NCT01489189

Heart Disease
(33 clinical trials recruiting)

Study 1:

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

http://ClinicalTrials.gov/show/NCT01508910

Study 2:

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

http://ClinicalTrials.gov/show/NCT01225562

Study 3:

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

http://ClinicalTrials.gov/show/NCT00683696

Study 4:

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

http://ClinicalTrials.gov/show/NCT01531374

Study 5:

A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

http://ClinicalTrials.gov/show/NCT01643330

Study 6:

Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter

http://ClinicalTrials.gov/show/NCT01253200

Study 7:

RED-HF™ Trial—Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

http://ClinicalTrials.gov/show/NCT00358215

Study 8:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

http://ClinicalTrials.gov/show/NCT00968708

Study 9:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

http://ClinicalTrials.gov/show/NCT01147250

Study 10:

INcrease Of VAgal TonE in CHF

http://ClinicalTrials.gov/show/NCT01303718

Study 11:

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

http://ClinicalTrials.gov/show/NCT01732822

Study 12:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

http://ClinicalTrials.gov/show/NCT01327846

Study 13:

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

http://ClinicalTrials.gov/show/NCT01442038

Study 14:

ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients

http://ClinicalTrials.gov/show/NCT01424722

Study 15:

Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Patients

http://ClinicalTrials.gov/show/NCT01626079

Study 16:

AngelMed for Early Recognition and Treatment of STEMI

http://ClinicalTrials.gov/show/NCT00781118

Study 17:

Premium Migraine Trial

http://ClinicalTrials.gov/show/NCT00355056

Study 18:

Post-Myocardial Infarction Remodeling Prevention Therapy

http://ClinicalTrials.gov/show/NCT01213251

Study 19:

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure

http://ClinicalTrials.gov/show/NCT01112579

Study 20:

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

http://ClinicalTrials.gov/show/NCT01670981

Study 21:

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

http://ClinicalTrials.gov/show/NCT01076764

Study 22:

Cardiox Shunt Detection Technology Study

http://ClinicalTrials.gov/show/NCT01333761

Study 23:

ABLATE AF Registry Trial

http://ClinicalTrials.gov/show/NCT01174745

Study 24:

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

http://ClinicalTrials.gov/show/NCT00958841

Study 25:

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

http://ClinicalTrials.gov/show/NCT01314313

Study 26:

AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

http://ClinicalTrials.gov/show/NCT01495364

Study 27:

Vest Prevention of Early Sudden Death Trial and VEST Registry

http://ClinicalTrials.gov/show/NCT01446965

Study 28:

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

http://ClinicalTrials.gov/show/NCT01729871

Study 29:

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

http://ClinicalTrials.gov/show/NCT01522651

Study 30:

Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients

http://ClinicalTrials.gov/show/NCT00981591

Study 31:

Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia

http://ClinicalTrials.gov/show/NCT01401647

Study 32:

A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

http://ClinicalTrials.gov/show/NCT01602328

Study 33:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

http://ClinicalTrials.gov/show/NCT01101035

Mental Illness
(49 clinical trials recruiting)

Study 1:

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

http://ClinicalTrials.gov/show/NCT01360632

Study 2:

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

http://ClinicalTrials.gov/show/NCT01360645

Study 3:

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

http://ClinicalTrials.gov/show/NCT01081132

Study 4:

Adult Attention Deficit Hyperactivity Disorder

http://ClinicalTrials.gov/show/NCT01692782

Study 5:

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

http://ClinicalTrials.gov/show/NCT01592786

Study 6:

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

http://ClinicalTrials.gov/show/NCT00637494

Study 7:

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01469377

Study 8:

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

http://ClinicalTrials.gov/show/NCT01432444

Study 9:

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

http://ClinicalTrials.gov/show/NCT01467700

Study 10:

Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)

http://ClinicalTrials.gov/show/NCT01349907

Study 11:

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

http://ClinicalTrials.gov/show/NCT01305408

Study 12:

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients

http://ClinicalTrials.gov/show/NCT01467713

Study 13:

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907}(P06107 AM3)

http://ClinicalTrials.gov/show/NCT01244815

Study 14:

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

http://ClinicalTrials.gov/show/NCT01361555

Study 15:

Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01564862

Study 16:

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder (VLZ-MD-05)

http://ClinicalTrials.gov/show/NCT01629966

Study 17:

A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

http://ClinicalTrials.gov/show/NCT01192867

Study 18:

An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

http://ClinicalTrials.gov/show/NCT01715805

Study 19:

Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

http://ClinicalTrials.gov/show/NCT01396447

Study 20:

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

http://ClinicalTrials.gov/show/NCT01500200

Study 21:

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

http://ClinicalTrials.gov/show/NCT01192906

Study 22:

A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

http://ClinicalTrials.gov/show/NCT01187407

Study 23:

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

http://ClinicalTrials.gov/show/NCT01371708

Study 24:

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

http://ClinicalTrials.gov/show/NCT01718509

Study 25:

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

http://ClinicalTrials.gov/show/NCT01235520

Study 26:

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

http://ClinicalTrials.gov/show/NCT01371721

Study 27:

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

http://ClinicalTrials.gov/show/NCT01396421

Study 28:

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01482221

Study 29:

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

http://ClinicalTrials.gov/show/NCT01515423

Study 30:

PEARL Schizophrenia Maintenance

http://ClinicalTrials.gov/show/NCT01435928

Study 31:

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

http://ClinicalTrials.gov/show/NCT01371734

Study 32:

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

http://ClinicalTrials.gov/show/NCT01688037

Study 33:

The Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome

http://ClinicalTrials.gov/show/NCT01569438

Study 34:

Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01364649

Study 35:

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01436149

Study 36:

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

http://ClinicalTrials.gov/show/NCT01372150

Study 37:

Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896 AM2)

http://ClinicalTrials.gov/show/NCT01190254

Study 38:

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

http://ClinicalTrials.gov/show/NCT01149655

Study 39:

Efficacy and Safety of TBS-2 Testosterone Gel in Pre-Menopausal Women With Acquired Female Orgasmic Disorder

http://ClinicalTrials.gov/show/NCT01607658

Study 40:

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

http://ClinicalTrials.gov/show/NCT01566162

Study 41:

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

http://ClinicalTrials.gov/show/NCT01521663

Study 42:

Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897 AM2 EXT)

http://ClinicalTrials.gov/show/NCT01190267

Study 43:

A Study in Prevention of Re-emergence of Depression Symptoms

http://ClinicalTrials.gov/show/NCT01299272

Study 44:

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

http://ClinicalTrials.gov/show/NCT01677182

Study 45:

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

http://ClinicalTrials.gov/show/NCT01718483

Study 46:

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

http://ClinicalTrials.gov/show/NCT01235585

Study 47:

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

http://ClinicalTrials.gov/show/NCT01397786

Study 48:

Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease

http://ClinicalTrials.gov/show/NCT01590888

Study 49:

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

http://ClinicalTrials.gov/show/NCT01369095

Stroke
(10 clinical trials recruiting)

Study 1:

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

http://ClinicalTrials.gov/show/NCT01273337

Study 2:

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

http://ClinicalTrials.gov/show/NCT00856661

Study 3:

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

http://ClinicalTrials.gov/show/NCT01225562

Study 4:

Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

http://ClinicalTrials.gov/show/NCT01098981

Study 5:

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

http://ClinicalTrials.gov/show/NCT00106938

Study 6:

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

http://ClinicalTrials.gov/show/NCT01732822

Study 7:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

http://ClinicalTrials.gov/show/NCT01327846

Study 8:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

http://ClinicalTrials.gov/show/NCT00968708

Study 9:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

http://ClinicalTrials.gov/show/NCT01101035

Study 10:

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

http://ClinicalTrials.gov/show/NCT01344447

PhRMA
RESEARCH • PROGRESS • HOPE

Pharmaceutical Research and Manufacturers of America
950 F Street, NW, Washington, DC 20004
www.phrma.org

place union bug here